Itareparib
Based on 1 Customer Validation
Itareparib (NMS-03305293; NMS-293) is a selective, orally active, blood-brain barrier-permeable PARP1 inhibitor with an IC50 < 0.01 μM. Itareparib does not form PARP1-DNA trapping complexes, avoids PARP-DNA "retention", reduces PAR levels and inhibits the growth of homologous recombination-deficient cells. Itareparib can be used in research on advanced solid tumors, recurrent gliomas and other conditions.
For research use only. We do not sell to patients.
- Purity: 99.24%
- CAS No.: 1606995-47-4
- Formula: C20H26FN3O2
- Molecular Weight:359.44
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
|
PARP1 < 0.01 μM (IC50) |
Itareparib selectively inhibits the growth of HR-deficient cells and reduces cellular PAR levels in vitro[1].
Itareparib exerts no damage to normal myeloid cells, indicating that it carries a lower risk of hematological toxicity compared with non-selective PARP inhibitors[2].
Itareparib exhibits potent antiproliferative activity in BRCA-mutated breast cancer cell lines[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1606995-47-4
-
Appearance Solid
-
Molecular Weight 359.44
-
Formula C20H26FN3O2
-
Color White to off-white
-
SMILES
O=C(C1=CC(F)=CC2=C1C(N(C3CCN(C4CCCCC4)CC3)C2)=O)N
-
Synonyms
NMS-03305293; NMS-293
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 4.17 mg/mL (11.60 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Li Q, et al. A new wave of innovations within the DNA damage response. Signal transduction and targeted therapy. 2023 Sep 08;8(1):338. [Content Brief]
[2]. Ray A, et al. Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors. Current breast cancer reports. 2025;17(1):22. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7821 mL | 13.9105 mL | 27.8211 mL | 69.5526 mL |
| 5 mM | 0.5564 mL | 2.7821 mL | 5.5642 mL | 13.9105 mL | |
| 10 mM | 0.2782 mL | 1.3911 mL | 2.7821 mL | 6.9553 mL |
- Itareparib
- 1606995-47-4
- NMS-03305293
- NMS-293
- NMS03305293
- NMS 03305293
- NMS293
- NMS 293
- NMS-293
- PARP
- glioma
- IDH wild type glioblastoma multiforme
- normal myelocytes
- PARP2
- homologous recombination deficient cells
- advanced solid tumors
- glioblastoma
- cell-derived xenograft models
- BRCA-mutated breast cancer cells
- PARP1
- Inhibitor
- inhibitor
- inhibit